Lilly claims pill market share

Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking Foundayo, the company's oral obesity drug.

“one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo”

Lilly breaks ground in Houston

Lilly broke ground on a six point five billion dollar manufacturing facility at Generation Park in Houston, Texas, expected to be operational by twenty thirty.

Plant will make Foundayo and more

The Houston facility will produce Foundayo and active ingredients for Lilly's other small-molecule medicines across cardiometabolic health, oncology, immunology and neuroscience.

Medicare coverage drives demand

Seven hundred thousand U.S. seniors started on GLP-1s after Medicare coverage began on July first, with seventy percent of those patients on Lilly's drugs.

Foundayo sales accelerate

Foundayo, which entered the U.S. market in April, booked ninety eight million dollars in sales for the second quarter, its first three-month period on the market.

Lilly's manufacturing bet

Since twenty twenty, Lilly has committed more than fifty billion dollars to expanding its manufacturing network to meet growing demand for obesity and diabetes treatments.